B
Botulinum toxin type A complex [Nabota]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Botulinum toxin type A complex
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials
for the management of focal spasticity of the lower limbs associated with stroke in adults who:
have a score of 3 or more on the Modified Ashworth Scale at the target muscle intended for botulinum toxin A treatment;
do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle; and
are concurrently receiving physiotherapy.
Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.
Funding status
[R] Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2023.
[R] Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials are recommended for inclusion on the MAF for the abovementioned indication from 1 November 2025.
[NR] MAF assistance does not apply to Botox 200 units injection vial or other brands of botulinum toxin A.
The Ministry of Health’s Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials
for the management of focal spasticity of the upper limbs associated with stroke in adults who:
have a score of 2 or more on the Modified Ashworth Scale at the target muscle intended for botulinum toxin A treatment;
do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle; and
are concurrently receiving physiotherapy.
Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.
Funding status
[R] Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 2 September 2019.
[R] Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials are recommended for inclusion on the MAF for the abovementioned indication from 1 November 2025.
[NR] MAF assistance does not apply to Botox 200 units injection vial or other brands of botulinum toxin A.
16/09/2025 Botulinum toxin A for treating blepharospasm or hemifacial spasm
The Ministry of Health’s Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials
for treating adults with blepharospasm or hemifacial spasm.
Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.
Funding status
[R] Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 2 September 2019.
[R] Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials are recommended for inclusion on the MAF for the abovementioned indications from 1 November 2025.
[NR] MAF assistance does not apply to Botox 200 units injection vial or other brands of botulinum toxin A.
16/09/2025 Botulinum toxin A for treating cervical dystonia
The Ministry of Health’s Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials
for treating adults with cervical dystonia.
Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.
Funding status
[R] Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 2 September 2019.
[R] Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials are recommended for inclusion on the MAF for the abovementioned indication from 1 November 2025.
[NR] MAF assistance does not apply to Botox 200 units injection vial or other brands of botulinum toxin A.
The Ministry of Health’s Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials
for treating children, aged 2 years or older, with focal spasticity of the upper or lower limbs (including dynamic equinus foot deformity) due to cerebral palsy, and who:
do not have significant joint contractures, i.e. the affected joint is not permanently fixed in position due to shortening of the target muscle; and
are concurrently receiving ongoing supportive therapy, e.g. physiotherapy or occupational therapy.
Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.
Funding status
[R] Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 2 September 2019.
[R] Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials are recommended for inclusion on the MAF for the abovementioned indication from 1 November 2025.
[NR] MAF assistance does not apply to Botox 200 units injection vial or other brands of botulinum toxin A.
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Intramuscular
* Clinical information is available for this product.